Genocea to Present at the UBS Global Healthcare Conference

CAMBRIDGE, Mass.--()--Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Jonathan Poole, Chief Financial Officer, will present a company overview at the upcoming UBS Global Healthcare Conference. The presentation is scheduled for Wednesday, May 20, 2015 at 11:00 a.m. EDT in New York, NY.

A live webcast of the presentation can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.

About Genocea Biosciences, Inc.

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-directed product candidates includes GEN-003 to treat genital herpes, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV prophylaxis, malaria and cancer immunotherapies. For more information, please visit the company's website at www.genocea.com.

Contacts

For media:
Spectrum Science Communications
Megan Lustig, O: 202-955-6222
mlustig@spectrumscience.com
or
For investors:
Genocea Biosciences, Inc.
Jonathan Poole, O: 617-876-8191
jonathan.poole@genocea.com

Genocea Biosciences, Inc.